Applying S1P Therapeutics to Improve Outcomes for Patients with Moderate to Severe Ulcerative Colitis

Date/Time

Sunday, May 23rd, 2021
8:00 am – 9:30 am Eastern Time

Location

Virtual, Live Streamed Program

Program Overview 

This interactive CME program will highlight sphingosine-1-phosphate (S1P) therapeutics to improve outcomes for patients with moderate to severe ulcerative colitis. The expert faculty, led by Dr. William J. Sandborn, will review S1P receptor modulators as a therapeutic target to support the management of ulcerative colitis. The faculty will then analyze clinical trial data for the safety and efficacy of novel S1P therapeutics to treat patients with ulcerative colitis. Additionally, a review of best practices for developing treatment strategies for patients with moderate to severe ulcerative colitis will be discussed. The faculty will conclude with an interactive panel discussion, delving into sphingosine-1-phosphate receptor modulator science as a therapeutic target to improve outcomes in patients with ulcerative colitis.

Educational Objectives

1. Understand the sphingosine-1-phosphate (S1P) receptor modulator as a therapeutic target to support the management of ulcerative colitis
2. Analyze recently completed and ongoing clinical trials for the efficacy and safety of novel S1P therapeutics to treat patients with moderate to severe ulcerative colitis
3. Develop treatment strategies for the application of novel therapeutics to treat patients with moderate to severe ulcerative colitis

Agenda

1. Welcome and Introductions – William J. Sandborn, MD
2. Scientific Update for Sphingosine-1-Phosphate (S1P) Receptor Modulators as a Therapeutic Target for UC – William J. Sandborn, MD
3. A Clinical Trial Review and Analysis on the Safety and Efficacy of Novel S1P Therapeutics for the Management of Moderate to Severe Ulcerative Colitis Disease – David T. Rubin, MD
4. Treatment Strategies for the Interprofessional Healthcare Team to Apply Novel Therapeutics to Optimize Patient Outcomes – Miguel Regueiro, MD

Chair

William J. Sandborn, MD
Professor and Chief, Division of Gastroenterology
Director, UCSD IBD Center
University of California, San Diego
San Diego, CA

Faculty

Miguel Regueiro, MD
Chair, Department of Gastroenterology, Hepatology, and Nutrition
The Pier C. and Renee A. Borra Family Endowed Chair in Gastroenterology and Hepatology
Vice Chair, Digestive Disease and Surgery Institute
Professor of Medicine
Cleveland Clinic
Cleveland, OH

David T. Rubin, MD
Joseph B. Kirsner Professor of Medicine
Section Chief, Gastroenterology, Hepatology and Nutrition
Co-Director, Digestive Diseases Center
University of Chicago Medicine
Chicago, IL

Accreditation Statements

In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation Statements

AcademicCME designates this live material for a maximum of 1.5 AMA PRA Category 1 Credits™. Participants should claim only the credit commensurate with the extent of their participation in the activity.

CE Inquiries/Special Needs

For all CME inquiries or special needs, please contact [email protected] or 610-687-3300.

Financial Support

This activity has been supported by an independent educational grant from Bristol Myers Squibb

 

Provided by AcademicCME

 

 

*This symposium is not part of the official Digestive Disease Week® (DDW) 2021 Meeting. 

*Further details regarding how to tune in to this virtual symposium will be emailed to the address used to register prior to the event.

For more information, feel free to check back to this page closer May 23rd or follow @academiccme on Twitter for real-time updates.  You can also email [email protected] with any questions.